Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions
Abstract Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads, leading to improved tumor delivery of the latter. After improving outcomes for patients with metastatic disease, ADC testing moved to the curative setting, where already one agen...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00800-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849764524072108032 |
|---|---|
| author | Pooja Patel Antonio Giordano Sara Giordano Ilana Schlam Sara M. Tolaney Paolo Tarantino |
| author_facet | Pooja Patel Antonio Giordano Sara Giordano Ilana Schlam Sara M. Tolaney Paolo Tarantino |
| author_sort | Pooja Patel |
| collection | DOAJ |
| description | Abstract Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads, leading to improved tumor delivery of the latter. After improving outcomes for patients with metastatic disease, ADC testing moved to the curative setting, where already one agent (trastuzumab emtansine) has been approved, after demonstrating to improve overall survival. Herein, we review the rationale, evidence, and challenges with the use of ADCs in the early-stage setting. |
| format | Article |
| id | doaj-art-b35aa4dc4b27411085adcd4f6cefc8d1 |
| institution | DOAJ |
| issn | 2374-4677 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj-art-b35aa4dc4b27411085adcd4f6cefc8d12025-08-20T03:05:07ZengNature Portfolionpj Breast Cancer2374-46772025-07-011111910.1038/s41523-025-00800-4Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutionsPooja Patel0Antonio Giordano1Sara Giordano2Ilana Schlam3Sara M. Tolaney4Paolo Tarantino5Medical Oncology, Dana-Farber Cancer InstituteMedical Oncology, Dana-Farber Cancer InstituteMedical Oncology, Dana-Farber Cancer InstituteMedical Oncology, Dana-Farber Cancer InstituteMedical Oncology, Dana-Farber Cancer InstituteMedical Oncology, Dana-Farber Cancer InstituteAbstract Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads, leading to improved tumor delivery of the latter. After improving outcomes for patients with metastatic disease, ADC testing moved to the curative setting, where already one agent (trastuzumab emtansine) has been approved, after demonstrating to improve overall survival. Herein, we review the rationale, evidence, and challenges with the use of ADCs in the early-stage setting.https://doi.org/10.1038/s41523-025-00800-4 |
| spellingShingle | Pooja Patel Antonio Giordano Sara Giordano Ilana Schlam Sara M. Tolaney Paolo Tarantino Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions npj Breast Cancer |
| title | Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions |
| title_full | Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions |
| title_fullStr | Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions |
| title_full_unstemmed | Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions |
| title_short | Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions |
| title_sort | antibody drug conjugates for treating early stage breast cancer current use anticipated evolutions |
| url | https://doi.org/10.1038/s41523-025-00800-4 |
| work_keys_str_mv | AT poojapatel antibodydrugconjugatesfortreatingearlystagebreastcancercurrentuseanticipatedevolutions AT antoniogiordano antibodydrugconjugatesfortreatingearlystagebreastcancercurrentuseanticipatedevolutions AT saragiordano antibodydrugconjugatesfortreatingearlystagebreastcancercurrentuseanticipatedevolutions AT ilanaschlam antibodydrugconjugatesfortreatingearlystagebreastcancercurrentuseanticipatedevolutions AT saramtolaney antibodydrugconjugatesfortreatingearlystagebreastcancercurrentuseanticipatedevolutions AT paolotarantino antibodydrugconjugatesfortreatingearlystagebreastcancercurrentuseanticipatedevolutions |